Background {#Sec1}
==========

The primary management of patients with a gynecological malignancy is usually protocol driven, and is seldom controversial, but the management of patients with recurrent disease is often contentious. It requires a multidisciplinary team discussion, and complex decisions around the possible roles of surgery, chemotherapy, radiation therapy or hormonal therapy. Often, a combination of therapies will be required.

Historically, patients with metastases in the lungs, liver or brain have been treated with palliative intent. Surgery is proving to have an increasing role in the management of such patients, and survivals are surprisingly good in many cases.

We undertook a search of the English literature over the past 25 years to seek references to the surgical management of lung, liver or brain metastases from cancers of the endometrium, ovary or cervix. The MEDLINE/PubMed database was searched, using the keywords metastases, lungs, liver, brain, endometrium, ovary and cervix.

Surgical management of lung metastases {#Sec2}
======================================

The first successful lobectomy for lung metastases in the 20^th^ century was reported by Barney and Churchill in 1939 \[[@CR1]\]. The patient was a 55-year old woman with a metastatic renal cell carcinoma, and she survived disease-free for 23 years Subsequently, there have been a number of reports of pulmonary metastasectomy for a variety of tumors \[[@CR2]--[@CR8]\], and the commonest primary epithelial tumour sites have been the colon, rectum, kidney and breast \[[@CR9]\].

Endometrial cancer is the commonest gynecological cancer in Western countries, and the majority of patients are diagnosed with disease confined to the corpus \[[@CR10]\]. The lungs are the commonest site of hematogenous spread for patients with advanced endometrial cancer \[[@CR11], [@CR12]\], but lung metastasis may occasionally occur with very early stage disease \[[@CR13]\].

The commonest gynaecological cancer in developing countries is cervical cancer \[[@CR14]\]. A review of the records of 2075 Sri Lankan women treated for cervical cancer from 1989 to 1993 reported that 38 patients (1.8 %) developed lung metastases, with a median interval from diagnosis of 9 months \[[@CR15]\].

Diagnosis {#Sec3}
---------

Most recurrences in the lungs are diagnosed by the investigation of symptoms, or of rising CA125 titers in the case of ovarian cancer. Barter et al. reported that there was no indication for routine chest x-ray in the follow-up of patients with cervical cancer, as there was no significant survival difference between symptomatic and asymptomatic patients \[[@CR16]\].

Imaging {#Sec4}
-------

Thoracic metastases from gynecologic malignancies exhibit various imaging patterns \[[@CR17]\]. Metastases from endometrial cancer typically manifest as pulmonary nodules and lymphadenopathy, whereas ovarian cancer often manifests with small pleural effusions and subtle pleural nodules. Most squamous cervical carcinomas manifest as solid pulmonary nodules, but cavitation occurs reasonably frequently. A "halo sign" is sometimes seen in hemorrhagic metastatic choriocarcinoma. Metastases from common gynecologic malignancies may be subtle and mimic benign condition such as intrapulmonary lymph nodes or granulomatous disease \[[@CR17]\]. If a solitary lung lesion is found, it is always important to consider the possibility of primary lung cancer.

The spiral computed tomographic (CT) scan has revolutionized the identification of small lung metastases. Before the advent of spiral CT technology, bimanual palpation of the lung through an open thoracotomy or sternotomy was considered necessary to avoid missing small lesions \[[@CR9]\]. The spiral CT scan has allowed better characterisation of both location and resectability of pulmonary nodules, so minimally invasive surgery has become a more attractive option \[[@CR18]\].

A preoperative PET/CT is desirable to exclude disease beyond the lungs, which would make pulmonary resection inadvisable in most cases.

Indications for pulmonary metastasectomy {#Sec5}
----------------------------------------

Specific criteria vary considerably in the literature. Clearly, there needs to be an adequate pulmonary reserve, and a limited number of lung metastases. A solitary metastasis is ideal, and 2 papers have reported a 100 % 5-year survival for a total of 21 patients with a solitary endometrial lung metastasis treated with wedge resection and adjuvant hormonal therapy \[[@CR11], [@CR19]\]. The estrogen and progesterone receptor (ER/PR) status should be obtained at the time of metastacectomy for endometrial cancer \[[@CR20]\].

Except for patients with ovarian cancer, whose tumors are often quite sensitive to chemotherapy or targeted therapy, it is preferable to have no spread beyond the thorax. A disease-free interval of at least 12, but preferably 24 months, is an important prognostic factor \[[@CR9], [@CR19], [@CR21]--[@CR23]\].

Surgical technique {#Sec6}
------------------

The operative procedure of choice is a wedge resection. Seki et al. stated that this should be performed with a disease-free margin of at least 2 cm for patients with metastatic lesions smaller than 3 cm diameter. Lobectomy was recommended for lesions larger than 3 cm, because of the greater risk of microscopic satellite lesions \[[@CR24]\].

Although most reports are of open thoracotomies, video-assisted thoracic surgery (VATS) has recently become an accepted and often preferred modality in patients with a limited number of metastases, either unilateral or bilateral \[[@CR18]\]. It is usually associated with a shorter hospital stay, and preserves the ability of the patient to undergo repeated resections, which may be necessary to achieve cure \[[@CR9]\].

Mediastinal lymphadenectomy was recommended by Seki et al. for metastatic squamous cell carcinomas 3 cm or more in diameter \[[@CR24]\]. In the paper from the Mayo clinic, there was no association between lymphadenectomy and survival, but the number of positive nodes was small \[[@CR23]\]. On the evidence available, resection of at least bulky nodes only would seem to be a reasonable option.

Reported series {#Sec7}
---------------

The findings of reported series with 5 or more patients are summarised in Table [1](#Tab1){ref-type="table"}. Although small series had been reported earlier \[[@CR2], [@CR25], [@CR26]\], the first major report of resection of pulmonary metastases from a gynecological cancer came from Memorial Sloan Kettering Cancer Center in 1992 \[[@CR27]\]. The study involved 45 patients whose pulmonary metastases from uterine sarcomas were resected between 1960 and 1989. All patients had a prior hysterectomy for uterine sarcoma, no extrathoracic tumor, and disease that was thought to be resectable. The mean age of the patients was 50 years, and the mean interval from hysterectomy to thoracotomy was 44 months (range 1 to 193 months).Table 1Major series reporting surgical management of pulmonary metastases from gynaecological malignanciesFirst Author Year of PublicationNumber of CasesPrimary TumourPattern of MetastasisSurgerySurvival/Recurrence OutcomesPrognostic FactorsAdachi \[[@CR29]\] 201523Epithelial gynecologic cancers Major series reporting suCervical -- 60.9 %\
Endometrial -- 17.4 %\
Ovarian -- 21.7 %1 nodule -- 69.6 %\
2--3 nodules -- 30.4 %VATS -- 56.5 %\
Conventional thoracotomy -- 43.5 %5 year OS:\
Cervical -- 61 %\
Endometrial -- 100 %\
Ovarian -- 100 %\
Recurrence -- 43.4 %Univariate analysis -- positive prognostic factors for survival:\
Endometrioid vs mucinous adenoca\
DFI \>2 yearsGonzalez Casaurran \[[@CR19]\] 201127Uterine and cervical cancer1 metastasis -- 66.7 %\
2 metastases -- 18.5 %\
≥2 metastases -- 14.8 %Surgical approach:\
- thoracotomy -- 81.5 %\
- sequential bilateral -- 7.4 %\
- unilateral VATS -- 3.7 %\
- sequential bilateral VATS -- 3.7 %\
- VATS + thoracotomy -- 3.7 %\
Lung resection:\
- Wedge resection -- 81.5 %\
- Lobectomy -- 11.1 %\
- Other -- 7.4 %\
Second surgery for metastases - 18.5 %Median survival from diagnosis of metastases -- 94 months\
5-year OS after diagnosis of metastases -- 84.1 %\
Overall relapse rate 44 %Positive prognostic factors\
Primary site -- endometrial vs cervical (*P* = 0.023)\
DFI \>24 months (*p* = 0.054)Burt \[[@CR22]\] 201182Sarcoma\
Included male and female patients\
Leiomyosarcoma -- 31 cases (38 %) - 24 pts (77 %) of these were female\
In female pts, uterus most common primary siteSolitary metastases -- 16 pts (52 %)\
Bilateral disease -- 19 %- Wedge resection -- 71 %\
- Lobectomy -- 23 %\
- Segmentectomy -- 6 %\
- VATS -- 58 %5 year survival:\
- Leiomyosarcoma -- 52 %\
- other sarcoma -- 32 %\
2^nd^ pulmonary metastasectomy -- 58.5 %\
Second pulmonary recurrence - 30.5 %Multivariate analysis -- DFI \>12 months from time of primary tumour resectionLim \[[@CR90]\] 201021Primary and recurrent cervical cancerNot reported23 resections in 21 patients\
- thorocatomies -- 43.5 %\
- VATS -- 52.2 %\
- VATS following thoracotomies -- 4.3 %\
Procedures -- 49\
- wedge resections -- 51.1 %\
- lobectomies -- 18.4 %\
- mediastinal LN dissections -- 24.5 %\
- segmentectomy -- 2.0 %\
- diaphragmatic resection −2.0 %\
- pleurectomy -- 2.0 %Note -- only 14 patients had recurrent cervical cancer, and 1 patient had primary lung cancer and mediastinal LN metastasis from cervical cancer\
Median f/up 16 months (range 2--67)\
- 2 pts died of disease\
- 3 pts alive with disease\
- 16 pts alive without diseaseNot reportedClavero \[[@CR23]\] 200670Uterine corpus -- 52.9 %\
Endometrium -- 32.9 %\
Cervix -- 10.0 %\
Ovaries -- 2.9 %\
Vagina -- 1.3 %\
Histopathology:\
Leiomyosarcoma -- 41.4 %\
Adenocarcinoma -- 32.9 %\
Other sarcoma -- 15.7 %\
SCC −7.1 %\
Other -- 2.9 %Median number of lung metastases -- 2 (range 1--19)Wedge excision -- 63 %\
Lobectomy -- 20 %\
Bilobectomy -- 3 %\
Pneumonectomy -- 2.5 %\
Combination -- 12.5 %5-year OS 46.8 % (95 % CI 34.2-63.0 %)\
10 year OS -- 34.3 % (95 % CI 19.7-52.5 %)Factors that adversely affected survival:\
DFI between 1^st^ gynecologic procedure and pulmonary resection \<24 months (*p* = 0.004)\
Primary site in cervix (*p* \< 0.001)Yamomoto \[[@CR28]\] 200429 (out of 7748 = 0.37 %)Cervical cancer (Stage Ib or II treated with curative intent surgery or radiotherapy)Solitary metastasis -- 58.6 %\
Multiple metastases -- 43.4 %Wedge resection -- 27.6 %\
Segmentectomy -- 6.9 %\
Lobectomy -- 65.5 %\
Hilar or mediastinal lymph node dissection -- 55.2 %5 year DFS after pulmonary metastasectomy -- 32.9 %For DFS:\
- ≤2 metastases\
- SCCAnraku \[[@CR21]\] 2004133Uterine malignancies (cervix and endometrium) Histopathology:\
SCC -- 43.6 %\
Cervical adenocarcinoma -- 9.8 %\
Endometrial adenocarcinoma -- 17.3 %\
Choriocarcinoma -- 12.0 %\
Leiomyosarcoma -- 4.7 %Solitary metastasis −58 %\
2--3 mets -- 23 %\
≥4 mets -- 17\
%Wedge resection -- 50 %\
Lobectomy -- 45 %\
Bilobectomy -- 2.5 %\
Pneumonectomy -- 2.5 %Overall survival after surgical resection:\
5-year -- 54.6 %\
10-year -- 44.9 %\
5-year survival by histpathological type:\
SCC -- 46.8 %\
Cervical adenoca -- 40.3 %\
Endometrial adenoca -- 75.7 %\
Choriocarcinoma -- 86.5 %\
Leiomyosarcoma -- 37.9 %Univariate analysis -- negative prognostic factors:\
Primary tumour in cervix\
DFI \<12 months\
Resection ≥ 4 mets\
Large tumour size (≥3 cm)\
Multivariate analysis:\
DFI \< 12 monthsAnderson \[[@CR20]\] 200182 eligible pts\
25 underwent pulmonary resectionEligible patients:\
Uterine -- 73.2 %\
Cervical -- 26.8 %\
Patients undergoing resection:\
Uterine -- 76.0 %\
Cervical -- 24.0 %Solitary -- 28 %\
Multiple -- 72 %Uterine:\
- Wedge -- 63.1 %\
- Lobectomy -- 10.5 %\
- Lobectomy/wedge -- 15.8 %\
- Bilobectomy -- 5.3 %\
- Segmentectomy -- 5.3 %\
Cervix:\
- Wedge -- 66.7 %\
- Lobectomy -- 33.3 %Uterine cancer\
- median survival 26 months\
- Leiomyosarcoma −25 months\
- Adenocarcinoma -- 46 months\
Cervix cancer\
- median survival 36 monthsUterine cancer -- favourable prognostic factors:\
Leiomyosarcoma vs adenocarcinoma (*p* = 0.02)Levenback \[[@CR27]\] 199245Uterine sarcomas:\
- Leiomyosarcoma -- 84 %\
- Endometrial stromal sarcoma -- 9 %\
- Mesodermal mixed tumours -- 7 %Unilateral lesions -- 71 %\
1 lesion -- 51 %\
Nodules \>2 cm -- 70 %Staged thoracotomies -- 100 %\
Median sternotomy and bilateral resections -- 4.4 %\
Incomplete resection -- 36 %From time of pulmonary resection:\
- 5 year survival -- 43 %\
- 10 year survival -- 35 %\
Median follow-up -- 89 months\
Disease recurrence -- 42 %Significant predictors:\
- unilateral vs bilateral disease\
Not significant:\
- metastasis size\
- number of metastases\
- disease free interval\
- patient age*VATS* video-assisted thoracoscopic surgery, *OS* overall survival, *DFI* disease free interval

All gross disease could be resected in 29 patients (64 %), the vast majority by wedge resection. The postoperative mortality was 2 % (one patient). The 5- and 10-year survival from the time of the pulmonary resection was 43 % and 35 % respectively, with a mean follow-up of 25 months. The mean survival for patients with bilateral disease was 27 months, while it was 39 months for patients with unilateral disease (*p* = 0.02).

A more recent paper looked at 82 male and female patients who underwent pulmonary resection for metastatic sarcoma with curative intent at the Brigham and Women's Hospital from 1989 to 2004 \[[@CR22]\]. Leiomyosarcomas accounted for 31 cases (38 %), and 77 % of leiomyosarcomas were in females. Patients with leiomyosarcomas had a better overall survival than patients with other sarcoma subtypes (70 versus 24 months; *p* = 0.049). Disease-free survival of greater than 12 months from time of primary tumor resection was the only significant prognostic factor in multivariate analysis. Systemic chemotherapy had no significant effect on long term survival.

In 2004, the Metastatic Lung Tumor Study Group of Japan reported the results of the largest series of patients having pulmonary metastasectomy for uterine malignancies. They reported on 133 patients undergoing surgery between March 1984 and February 2002 \[[@CR21]\]. The postoperative mortality was 0.8 % (1 case). The only significant prognostic factor in multivariate analysis was a disease-free interval of less than 12 months \[[@CR21]\].

Another Japanese study published in 2004 evaluated the role of resection of pulmonary metastases from patients with stage Ib or II cervical cancer who underwent curative initial treatment \[[@CR28]\]. The 5-year disease-free survival was 42 % for patients with one or two metastases, compared to 0 % for patients with three or four (*p* = 0.0003). Patients with squamous cancers had a 5-year disease-free survival of 47.4 %, compared to 0 % for patients with glandular cancers (*p* = 0.014)

A large series of surgical resections for lung metastases from gynaecological malignancies was reported from the Mayo Clinic in 2006 \[[@CR23]\]. They reported 70 patients with metastatic disease limited to the lungs who were treated between 1985 and 2001. Synchronous lung metastases were present in 9 patients (13 %). Post-operative morbidity occurred in 18 patients (26 %), and there was one postoperative death (1.4 %) \[[@CR23]\]. The overall survival for the group was 47 % at 5 years and 34 % at 10 years.

The most recent report was from Nagoya University Hospital in 2015 \[[@CR29]\]. They reviewed 37 patients with isolated lung metastases (\<3 nodules). They compared 23 patients who underwent surgical resection (cervical (14), endometrial (4) or ovarian (5) carcinomas), with 10 patients who underwent chemotherapy only. Among 6 patients who recurred in the lung a second time, 5 underwent a second pulmonary metastasectomy and all 5 patients were alive and well at the time of reporting. There was no significant difference in overall survival between patients having surgery or chemotherapy, but the numbers were small and the trend favoured surgery (81.7 % versus 49.5 %; *p* = 0.072). There was a significant survival advantage for patients with a disease-free survival of \> 24 months (*p* =0.006).

Surgical management of brain metastases {#Sec8}
=======================================

Brain metastases are common with breast, lung, and renal carcinomas, and malignant melanoma \[[@CR30], [@CR31]\], but are rare with gynaecological cancers, with the exception of choriocarcinoma \[[@CR32], [@CR33]\]. They are usually associated with widely disseminated disease.

Diagnosis {#Sec9}
---------

Symptoms of brain metastases may be subtle initially, and may include headaches, nausea, vomiting, confusion, dizziness, decreased mental status, general or extremity weakness, urinary incontinence, gait disturbance, ataxia, visual disturbance including diplopia, photophobia, speech impairment, syncope or seizures \[[@CR32]--[@CR36]\]. Increased intracranial pressure caused by associated brain edema leads to the development of papilledema in the fundus of the eye, which is a classical sign of a brain tumor \[[@CR37]\].

Imaging {#Sec10}
-------

Most brain metastases are diagnosed with a computed tomographic (CT) scan of the brain, which has been performed to investigate suspicious symptoms. The metastasis appears as a heterogeneous, contrast enhancing lesion \[[@CR35]\] (Fig. [1](#Fig1){ref-type="fig"}). Metastatic ovarian cancers can occasionally be calcified \[[@CR38]\]. Contrast-enhanced magnetic resonance imaging (MRI) is the most accurate modality to image the brain \[[@CR39]\].Fig. 1CT scan of the brain showing a solitary metastasis, 5x4 cm, in the right occipital lobe, with some extension to the parietal lobe. Note the heterogeneic appearance of the metastasis and the surrounding brain edema

Surgical Technique {#Sec11}
------------------

Traditionally, patients with solitary metastases have undergone metastasectomy and whole brain radiotherapy (WBRT) \[[@CR37], [@CR39]\]. The latter is associated with a number of late complications, including brain atrophy, necrosis, dementia, and endocrine dysfunction \[[@CR40]\].

More recently, stereotactic radiosurgery using a "gamma-knife" (GKRT) has become available \[[@CR37], [@CR41], [@CR42]\]. This is a technique that enables the precise delivery of a high-dose of gamma radiation to a small intracranial target, while sparing the surrounding normal brain. If there is a solitary lesion, surgical resection followed by GKRT to the tumor bed is ideal. GKRT offers an advantage if the lesion is inaccessible. Lesions larger than 3 cm are less likely to be controlled by GKRT \[[@CR41]\].

Indications for surgical resection {#Sec12}
----------------------------------

Ideally, suitable patients for brain metastasectomy would have a solitary lesion and no evidence of extracranial disease \[[@CR35], [@CR43]--[@CR45]\]. Such patients are uncommon, as the majority of patients have multiple brain metastases \[[@CR39], [@CR46]--[@CR49]\]. A well controlled primary tumor \[[@CR42], [@CR50]\] and a disease-free interval of at least 12 months is desirable, but Petru et al. reported a patient who had a solitary brain metastasis diagnosed prior to the diagnosis of endometrial cancer. She had stereotactic radiosurgery to the brain lesion, followed by aggressive cytoreductive surgery and doxorubin-based chemotherapy for the primary tumor, and remained alive and free of disease at 171 months \[[@CR51]\].

Brain metastases by primary site {#Sec13}
--------------------------------

There have been comprehensive reviews by Piura and Piura regarding brain metastases from gynaecological cancers \[[@CR32], [@CR33], [@CR37]\]. The incidence, pattern of brain metastasis, and survival by primary site are summarised in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.Table 2Summary of incidence, disease-free survival, and pattern of brain metastasis \[[@CR32], [@CR33], [@CR37]\]Primary SiteIncidenceMedian Disease-Free IntervalOnly site of metastatic diseaseSolitary metastasisOvarian (*n* = 521)1.19 % (413/34 728)24.3 months (11--46)46.8 % (236/504)41.9 % (205/489)Endometrial (*n* = 115)0.59 % (61/10 199)17 months (2--108)49 % (48/98)56.8 % (50/88)Cervical (*n* = 100)0.57 % (*n* = 65/11 249)18 months (0.25-105 months)46.8 % (37/79)50.6 % (40/79)Table 3Summary of survival outcomes after diagnosis of brain metastases \[[@CR32], [@CR33], [@CR37]\]Primary SiteMedian survival (months)Surgery alone (months)WBRT (months)Surgery + WBRT (months)Multimodal Surgery + RT +/− Chemo (months)Ovarian6.4 (1--28)6.74.51720Endometrial5 (0.1-171)2.25 (1--18)2 (0.25-17)Not available22 (2.1-84)Cervical4 (0.1-72)4 (1--7)3 (0.1-22.6) (+/− chemo)7.1 (1--72) (+/− chemo)SRS + other modality13.7 (5--22.5)*WBRT* whole brain radiotherapy, *RT* radiotherapy, *SRS* stereotactic radiosurgery

### Ovarian cancer {#Sec14}

Of the gynaecological cancers, ovarian cancer is associated with the highest incidence of brain metastases, and there have been two comprehensive reviews in the past 5 years. In 2011, Piura and Piura reported 521 cases between 1978 and 2011 \[[@CR32]\], while in 2014, Pakneshan et al. reported 591 cases between 1978 and 2013 \[[@CR45]\]. Piura and Piura determined the incidence of brain metastases from ovarian cancer to be 1.2 % \[[@CR32]\], which was twice the incidence associated with cervical \[[@CR37]\] or endometrial cancer \[[@CR33]\]. Pakneshan et al. reported that the incidence among the various studies ranged from 0.49 to 11.4 %, with an average of 2.55 % \[[@CR45]\]. A review of the literature reveals several case reports and small series, the largest being 72 patients \[[@CR47]\].

Since the advent of chemotherapy over 50 years ago, the incidence of brain metastases from ovarian cancer has increased, presumably because these patients are living longer, and because the chemotherapy has difficulty crossing the blood--brain barrier \[[@CR31]\]. A review of 3,690 patients with epithelial ovarian cancer treated at the Royal Marsden Hospital from 1980 to 2000 reported that the incidence of brain metastases increased from 0.2 % in 1980--84 to 1.3 % in 1995--99 (*p* \< 0.001) \[[@CR34]\].

Most patients have advanced stage, high-grade serous cancers at initial presentation \[[@CR35], [@CR45], [@CR47], [@CR48], [@CR52]--[@CR54]\], and the brain metastasis often follows a negative second-look laparotomy \[[@CR54]--[@CR56]\]. CA125 titers are not absolutely reliable in the screening for brain metastases \[[@CR57]\], although they are elevated in the majority of patients \[[@CR45], [@CR46]\].

In the review by Piura and Piura, the median interval from diagnosis to brain metastasis in 31 series was 24.3 months (range 11 to 46 months) \[[@CR32]\], although there was a case report of a patient who developed a brain metastasis 11 years after diagnosis of the primary cancer \[[@CR58]\]. The disease was confined to the central nervous system in 236 of 504 patients (46.8 %) \[[@CR32]\]. The brain parenchyma, most commonly the cerebrum, was the site of metastasis in 489 patients (97 %) and the leptomeninges in 15 cases (3 %). Most brain metastases were multiple (269 of 474; 56.8 %) \[[@CR32]\].

### Prognosis {#Sec15}

Survival by treatment type in patients with brain metastases from ovarian cancer is summarised in Table [4](#Tab4){ref-type="table"}. Surgical resection significantly improved the survival compared to other methods of treatment \[[@CR35], [@CR43], [@CR45], [@CR47], [@CR48], [@CR52], [@CR54], [@CR59], [@CR60]\]. Solitary metastases generally have a better prognosis \[[@CR35], [@CR43], [@CR45]\]. Cormio et al. reported 22 patients who had resection of a solitary metastasis \[[@CR44]\]. They reported that extracranial disease and the time interval between diagnosis of ovarian cancer and central nervous system involvement were the only factors significantly affecting survival. There were no operative deaths, and low morbidity. The majority of patients had complete resolution of their neurological symptoms \[[@CR44]\].Table 4Ovarian cancer with brain metastases -- survival by treatment modality after diagnosis of brain metastases \[[@CR32]\]Treatment modalityMedian survival (months)% of patients (n)\
Total = 538WBRT^\*^ only4.535 % (182)Surgery + WBRT1715.2 % (79)WBRT + chemo9.113.5 % (70)Surgery + WBRT + chemo2013.3 % (69)Surgery only6.75 % (26)SRS^\*^ or GKRS^\*^183.8 % (20)Chemo only7.51.9 % (10)Surgery + chemoNot available1.3 % (7)No treatment (steroids only)1.411 % (57)\*WBRT whole brain radiationtherapy, SRS stereotactic radiosurgery, GKRS gamma knife radiosurgery

Aggressive management of multiple metastases is justified \[[@CR39], [@CR46]--[@CR49]\], particularly if the patient meets the criteria for Class I of the Radiation Therapy Oncology Group's recursive partitioning analysis system, ie., age \< 65 years, Karnofsky score \> 70, controlled primary disease and no extracranial metastases \[[@CR43]\]. Kawana et al. described a patient who was initially diagnosed with stage IVB ovarian cancer, and developed 3 brain metastases after a disease-free interval of 27 months \[[@CR41]\]. She underwent surgical resection of the two accessible lesions, and then gamma-knife radiotherapy for a third inaccessible lesion after 30Gy external beam local radiation to the bed of the resected tumors and the inoperable tumor. She remained disease-free at 5 years, with good quality of life \[[@CR41]\].

In their recent literature review, Piura and Piura reported that the median survival for patients having whole brain radiation was 4.5 months, compared to 17 months for patients having surgical resection plus radiation, and 20 months for the addition of chemotherapy \[[@CR32]\]. The outcomes for patients with brain metastases by treatment modality are summarised in Table [4](#Tab4){ref-type="table"}. In the review by Pakneshan et al., combination surgery, radiation and chemotherapy was associated with longer survival than whole brain radiation alone (20.5 months versus 9.1 months; *p* = 0.04) \[[@CR45]\]. Others have also stressed the need for aggressive multimodal therapy, including adjuvant chemotherapy \[[@CR47], [@CR52], [@CR59]--[@CR62]\], as the patients usually succumb to extracranial disease \[[@CR63]\].

Long term survival is possible. Micha el al reported a patient with a stage IIIC high-grade serous carcinoma who recurred in the cerebellum 27 months after diagnosis, and following primary cytoreductive surgery and platinum-based chemotherapy \[[@CR64]\]. She had surgery and whole brain radiation and was still alive and well 7 years post treatment for her brain metastasis. McMeekin also described a 7-year survivor \[[@CR60]\].

### Cervical cancer {#Sec16}

The most common site of distant metastases from cervical cancer is the lung \[[@CR65], [@CR66]\]. Brain metastases are rare. In a literature review in 2012, Piura and Piura reported only 96 cases, with an incidence of 0.57 % \[[@CR37]\]. The majority of patients had early stage disease at diagnosis -- 42.2 % had stage IB and 36.6 % stage II -- although 80 % of patients had poorly differentiated (grade 3) tumors. Histologic types basically reflected those expected in the general population, although there were 3 (3.6 %) small cell neuroendocrine carcinomas \[[@CR37]\].

The interval between primary diagnosis and brain metastasis ranged from 1 week to 105 months, with a median of 18 months. The brain metastasis was part of a disseminated recurrence in 53.2 % of patients, was solitary in 50.6 %, and was located only in the cerebrum in 73 % of patients. Some authors have noted that brain metastases from cervical cancer were rarely accompanied by systemic disease, but they were commonly accompanied by uncontrolled local-regional disease \[[@CR42], [@CR50]\].

### Prognosis {#Sec17}

Based on limited data in the literature, Piura and Piura determined that the median survival for no treatment was 0.6 months, for whole brain radiation (WBRT) 4 months, while for surgical resection followed by WBRT it was 7.1 months. The best median survival (13.7 months) was achieved with stereotactic radiation, either alone or combined with another modality \[[@CR37]\].

Robinson and Morris reported a patient with a brain metastasis from a squamous cell carcinoma of the cervix who remained disease free 6 years following surgical resection and whole brain radiation \[[@CR67]\]. Chura et al. reported 12 patients with brain metastases from cervical cancer, 8 of whom received WBRT, but their median survival was only 2.3 months \[[@CR68]\].

### Endometrial Cancer {#Sec18}

Brain metastases from endometrial cancer are rare, with Piura and Piura documenting only 115 cases from 35 published papers, with an incidence of 0.59 % \[[@CR33]\]. The brain metastasis was diagnosed after a median interval of 17 months (range 2 to 108 months). In 4 patients (4.2 %), the primary and metastatic diagnoses were made simultaneously, and in 9 patients (9.5 %), the brain metastases were detected before the primary.

In the review by Piura and Piura, 63 % of patients (50 of 79) had advanced disease at initial diagnosis, and 78.1 % (57 of 73) had poorly differentiated tumors \[[@CR33]\]. Almost half the patients had metastases confined to the brain (48 of 98 patients; 49 %), and 56.8 % of patients (50 of 88) had a solitary metastasis. Site of metastasis was available for 66 patients, of whom 48 (72.7 %) had disease confined to the cerebellum \[[@CR33]\]. Of the 20 patients reported by Chura et al., 8 (40 %) had a single metastasis, 4 (20 %) had two, 7 (35 %) had 3 or more, and 1 patient (5 %) had leptomeningeal disease \[[@CR69]\].

### Prognosis {#Sec19}

In the review by Piura and Piura, the overall median survival after diagnosis of brain metastasis was 5 months (0.1 to 171 months). Patients having WBRT alone had a median survival of 2 months (0.25-17 months) while patients having surgical resection followed by WBRT had a median survival of 22 months (2.1-84 months) \[[@CR33]\]. Orrru et al. reported 2 patients treated by surgical resection followed by WBRT who were alive and well at 16 and 64 months respectively \[[@CR70]\].

Surgical management of liver metastases {#Sec20}
=======================================

The literature on liver resection for metastatic gynecological cancer is limited. It has been estimated that up to 50 % of patients who die of cervical, endometrial or ovarian cancer will have liver metastases at autopsy \[[@CR71], [@CR72]\], but probably only 1 - 10 % would be suitable for liver resection \[[@CR73]\]. Gynecologic cancers that metastasize to the liver usually do so in the setting of obvious regional or systemic dissemination \[[@CR71], [@CR74]\].

Surgical technique {#Sec21}
------------------

Hepatic resection has evolved, with improved surgical techniques, instrumentation, anesthesia and perioperative care, and now carries a very low morbidity and mortality \[[@CR73], [@CR75], [@CR76]\].

Hepatic resection usually involves non-anatomical wedge resection (Fig. [2](#Fig2){ref-type="fig"}), but anatomical resection of one or more liver segments may also be performed \[[@CR77]\]. Resection of as much as 70 % of the liver can be performed, with a mortality rate of less than 5 % in major hepatobiliary centers \[[@CR77], [@CR78]\]. Over the past 15 years, radiofrequency ablation, usually in conjunction with surgical resection, has extended the cohort of patients with surgically treatable disease, and helped achieve better locoregional control \[[@CR79], [@CR80]\].Fig. 2Non-anatomical liver resection for a patient with ovarian cancer with involvement of the liver capsule and underlying parenchyma

Indications {#Sec22}
-----------

Liver surgery should only be considered when all other metastatic disease is well controlled, when disease in the liver can be completely resected, or when liver resection is part of the achievement of optimal cytoreduction for patients with ovarian cancer \[[@CR81], [@CR82]\].

Results {#Sec23}
=======

The findings of reported series with 5 or more patients are summarised in Table [5](#Tab5){ref-type="table"}.Table 5Major series reporting surgical management of hepatic metastases from gynaecological malignanciesFirst Author Year of PublicationNumber of patientsPrimary vs Recurrent DiseasePrimary SiteMedian overall survival (from time of liver resection unless otherwise stated)Factors associated with longest survivalKolev \[[@CR91]\] 201427RecurrentOvary12 months\
(2--190)Interval from primary surgery of \>24 months (*P* = 0.044)\
Secondary cytoreduction to \<1 cm (*P* = 0.014)Neumann \[[@CR82]\] 201241PrimaryOvaryR0 -- 42 months\
R1 -- 4 months\
R2 -- 6 monthsPost operative residual tumour massRoh \[[@CR77]\] 201118RecurrentOvary38 months\
(3--78)Less abdominal than pelvic disease (38 vs 11 months, *P* = 0.032)\
Optimal cytoreduction (40 vs 9 months, *P* = 0.0004)\
Negative margin status of hepatic resection\
(40 vs (months, *P* = 0.0196Kamel \[[@CR92]\] 201152PrimaryOvary53 months\
5-year survival 41 %Not reportedKnowles \[[@CR93]\] 20105RecurrentEndometrioid (Ovarian or Endometrial)Median OS not reported\
DFS range 8--66 monthsNot reportedLim \[[@CR75]\] 200914PrimaryOvary5-year PFS by Stage:\
- IIIC -- 25 %\
- IV -- 23 %\
5-year OS by Stage:\
- IIIC -- 55 %\
- IV -- 51 %Not reportedLoizzi \[[@CR94]\] 200529Primary (Group 1) -- 8\
1^st^ Recurrence (Group 2) -- 10\
2^nd^ recurrence (Group 3) -- 11OvaryMedian survival from time of liver metastasis diagnosis:\
Group 1 -- 19 months\
Group 2 -- 24 months\
Group 3 -- 10 monthsCell type\
Performance status\
Number of hepatic lesions\
Presence of other sites of disease at time of diagnosis of hepatic metastasis\
Platinum based chemotherapyWeitz \[[@CR76]\] 200519RecurrentOvary -- 63.2 %\
Endometrium -- 21.1 %\
Cervix -- 10.5 %\
Fallopian tube -- 5.2 %Reproductive tract tumours (note -- included testicular cancer pts, but no difference between ovary and testicular survival)\
Median cancer specific survival reproductive tract primary -- 115 months\
Ovary - 3 year recurrence free survival 58 %Primary tumour type\
Length of disease free interval from primary tumourYoon \[[@CR95]\] 200324RecurrentOvary\
Fallopian tube62 months\
(6--94)No significant prognostic factors for OS identified on univariate analysisMerideth \[[@CR89]\] 200326RecurrentOvaryOverall median disease-related survival 26.3 months\>12 months since original diagnosis (27.3 vs 5.7 months, *P* = 0.004)\
≤1 cm residual disease (27.3 vs 8.6 months, *P* = 0.031)Fan \[[@CR96]\] 200118Ovary -- immature teratoma3-year survival -- 77.8 %\
5-year survival -- 55.6 %\
10-year survival -- 38.9 %Not reportedNaik \[[@CR97]\] 200037PrimaryOvary11 months\
2-year survival 23 %\
5-year survival 9 %Optimal surgery with residual \<2 cm (*P* = 0.0029) or \<1 cm (*P* = 0.0086)Bristow \[[@CR81]\] 199937PrimaryOvaryOptimal extrahepatic and hepatic resection -- 50.1 months\
Optimal extrahepatic resection with residual hepatic tumour -- 27.0 months\
Suboptimal with residual extrahepatic and heaptic tumour -- 7.6 monthsOptimal extrahepatic resection (*P* = 0.0001)Elias \[[@CR84]\] 19986Not statedGynecologic5-year survival -- 45 %Not reportedChi \[[@CR71]\] 199712RecurrentOvary -- 58 %\
Cervix -- 17 %\
Endometrium -- 17 %\
Fallopian tube -- 1 8 %27 months\
(Median f/up 25 months, range 8--94 months)Not reported*OS* overall survival, *DFS* disease-free survival, *PFS* progression-free survival

The first study by Brunchwig in 1963 \[[@CR83]\] reported 24 cases of hepatic lobectomy for metastatic carcinoma, 4 of whom were from the cervix or endometrium. Three of the four died in the perioperative period, and the fourth died of disease at 18 months..

In most large series of patients having partial hepatectomy for metastatic malignancy, gynaecological cancers represent less than 10 % of cases \[[@CR73], [@CR76], [@CR84]--[@CR86]\]. A large, multi-centre French study reported that during the 1980's, the median number of partial hepatectomies for non-colorectal, non-endocrine metastases per annum did not exceed 17, whereas it rose to 70 during the 1990's and 115 during the 2000's \[[@CR73]\].

In patients with colorectal and gut-associated endocrine tumors, the most likely mode of spread is via the portal venous system. The majority of the patient's tumor burden is thus confined to the abdomen \[[@CR73]\], and 5-year survivals of 45-50 % are routinely reported \[[@CR87], [@CR88]\]. By contrast, liver metastases from gynaecological cancers reach the liver via the systemic circulation, so other extra-abdominal sites are likely to be involved, which has fostered caution. Liver surgery should only be considered when the metastatic disease is well controlled or responding to systemic therapy, or when liver resection is part of the achievement of optimal cytoreduction for ovarian cancer \[[@CR81], [@CR82]\].

Lim et al. reported 16 patients who had parenchymal liver metastases at the time of diagnosis with advanced ovarian cancer \[[@CR75]\]. Two patients (12.5 %) had hematogenous metastases which were unresectable, while 14 (87.5 %) had parenchymal invasion from peritoneal seeding, and were able to undergo complete resection. These patients, who were officially FIGO stage IV, had the same survival as patients with Stage IIIC disease.

A series of 26 patients undergoing hepatic resection for metachronous metastases from ovarian cancer was reported from the Mayo Clinic in 2003 \[[@CR89]\]. The median age of the patients was 62 years and a solitary liver lesion was present in 17 patients (63.4 %). All patients had pelvic and abdominal disease in addition to the liver metastases and 42 % had a simultaneous bowel resection. Optimal cytoreduction (\<1 cm) was achieved in 21 patients (80.7 %). Segmentectomy was required in 18 patients (69.2 %) and right hepatectomy in 4 (15.4 %). There was no serious morbidity or mortality from the surgery. There was a significant survival advantage for patients whose disease-free interval was \>12 months (27.3 versus 5.7 months; *p* \< 0.004)), and for those having optimal cytoreduction (27.3 versus 8.6 months; *p* \< 0.031)

In 2006, a multicentre French study reported the largest series (1452) of patients who underwent hepatic resection for non-colorectal, non-endocrine liver metastases \[[@CR73]\]. Gynecologic cancer represented 126 cases (8.7 %), and although the patients were highly selected, the results were very satisfactory. Overall, the 5-year survival was 48 %. It was 50 % for patients with ovarian cancer and 35 % for patients with a uterine primary \[[@CR73]\]. For the 1452 patients the 60-day operative mortality was 2.3 %.

Conclusions {#Sec24}
===========

From a review of the current literature, it is apparent that surgery should play an increasing role in the management of patients with parenchymal metastases from gynecological cancers to the lungs, brain or liver. Appropriate patient selection is critical, but surprisingly good long-term survival results can be achieved for resection of metastases from all three organs, in conjunction usually with the use of adjuvant radiation, chemotherapy or hormonal therapy.

This requires the development of a committed, multidisciplinary team, working in a high volume tertiary center, where the necessary infrastructure for postoperative management is available. In these circumstances, postoperative morbidity and mortality are low.

Ideally, patients should have metastatic disease confined to the lungs, brain or liver, except in the case of a patient with a chemosensitive ovarian cancer, where resection of pulmonary or liver metastases may form part of the initial cytoreductive surgical effort. A solitary metastasis is ideal, but good results may be obtained with multiple metastases, as long as all macroscopic disease can be resected. A disease-free interval of at least 12 months, and preferably 24 months is desirable, together with a satisfactory performance status, and adequate functional reserve in the organ being partially resected.
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